Sales and net profit grew 7% and 8% year-over-year, with strong performance in wholesale, manufacturing, and clinical trials. The Group maintained market leadership, expanded its clinical trials segment, and increased its dividend, while managing risks and investing in future growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.